Asymchem Unveils 2026 H-Share Restricted Share Scheme; Up to 1.63 Million New Shares Planned for Employee Incentives

Asymchem Laboratories (Tianjin) Co., Ltd. (ASYMCHEM) announced that its board on 30 July 2026 approved a proposal to implement the “2026 H Share Restricted Share Scheme”, designed to incentivise directors, senior management and employees. The plan requires approval at an upcoming extraordinary general meeting (EGM).

The scheme aims to (1) reinforce long-term, sustainable growth, (2) enhance talent attraction and retention, and (3) better align management and shareholder interests. Eligible participants cover directors, senior management and other employees of the group.

Source and size of shares • Incentive shares may come from (i) on-market purchases, (ii) new H-share issues, or (iii) treasury shares. • The overall scheme mandate allows up to 4.31 million H shares, comprising 1.63 million new shares (representing 5.86% of current H-share capital) and 2.68 million shares to be acquired in the secondary market. • The aggregate cap for all existing share schemes is limited to 2.76 million H shares, equal to 10% of issued H-shares as at 3 April 2025.

Individual and governance limits • Any grant causing an individual’s cumulative awards across all schemes to exceed 1% of issued H-shares in any 12-month period will trigger separate shareholder approval. • Grants to directors, chief executives or substantial shareholders (and their associates) that exceed 0.1% of issued H-shares within 12 months require approval by independent non-executive directors and shareholders in accordance with Hong Kong Listing Rules.

Key terms • Issue price: RMB1.00 per incentive share (par value). • Vesting: 25% annually over four years; no tranche vests earlier than 12 months post-grant. • Performance: Vesting conditional on company-level and individual performance targets set in each Grant Instrument. • Clawback: The board may cancel unvested awards if misconduct, material loss caused, regulatory breaches or similar events occur.

Board authorisation Subject to EGM approval, the board (or its delegate) will be empowered to operate the scheme, grant awards, issue and list new shares, amend scheme rules within regulatory parameters, and handle related filings and capital adjustments. The authority will last for the duration of the scheme.

Regulatory and next steps The scheme complies with Chapter 17 of the Hong Kong Listing Rules and will only take effect upon shareholder approval at the forthcoming EGM. A circular detailing the scheme and authorisations will be dispatched in due course.